Comparison of intravenous Paracetamol with oral Ibuprofen for medical closure of PDA (patent ductus arteriosus) in preterm newborns – can it be an effective, safe and preferable choice?
Abstract
Introduction: In prematurely born newborns, the ductus arteriosus frequently fails to close and more than half of preterms might have Patent Ductus Arteriosus (PDA) after birth during the first 24hours. About 70% of infants born before 28 weeks may require medical or surgical closure of PDA.
Objectives: To compare the effect of i/v PCM and oral Ibuprofen on PDA closure rate in preterm neonates with a gestational age of < 37 weeks and evaluate the side effect profile of both drugs.
Material and Methods: This time-bound prospective observational study for comparison of the efficacy of the two drugs on the closure of PDA in preterms admitted during 1.5 years of the study period in a neonatal ICU caring for inborn as well as outborn neonates in central India. After approval of the institutional ethics committee, initial clinical screening included all preterms but only those with PDA (open ductus arteriosus) confirmed by 2D-echocardiography were allocated to receive either of two treatment regimens (3-day courses of each oral Ibuprofen and i/v PCM) which already exist as evidence-based therapeutic practice options.
Result: Out of a total of 43 cases clinically suspected on initial screening, 30 preterm babies confirmed by 2D-Echo to have PDA were finally enrolled and analysed. Twenty-one patients received i/v PCM with a resultant PDA closure rate of 85.7 % (n = 18/21), while nine cases could be allocated oral Ibuprofen arm and ductus closure was obtained in seven patients (77.78%). Although the PDA closure rate between two drug regimens was not statistically significant (p=0.593), i/v PCM resulted in slightly higher efficacy and fewer adverse effects.
Conclusion: Paracetamol, preferably by the intravenous route, seems to be an effective, cheap, easily available and safe first-line alternative to oral Ibuprofen for the closure of PDA, especially in newborns with extreme prematurity, who are initially intolerant to oral feeds or drugs.
Downloads
References
Sinha R, Dalal S, Negi V. An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol 2013; 2: 30.
Hamrick SEG, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125: 1020–1030.
Hammerman C. Patent ductus arteriosus: Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 1995; 22: 457–479.
Naulty CM, Horn S, Conry J, et al. Improved lung compliance after ligation of patent ductus arteriosus in hyaline membrane disease. J Pediatr 1978; 93: 682–684.
R M. Mathew R. In: WW F (ed) Development of the pulmonary circulation: metabolic aspects. Philadelphia: W.B. Saunders, 1998, pp. 924–9.
Edwards AD, Wyatt JS, Richardson C, et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet 1990; 335: 1491–1495.
Ohlsson A, Bottu J, Govan J, et al. Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus. Developmental Pharmacology and Therapeutics 1993; 20: 100–106.
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev; 2020. Epub ahead of print 2020. DOI: 10.1002/14651858.CD003481.pub8.
Sakhalkar VS, Merchant RH. Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin. Indian Pediatr 1992; 29: 313–318.
Grèen K, Drvota V, Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989; 37: 311–315.
Botting RM. Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3? Clin Infect Dis 2000; 31: S202–S210.
El-Khuffash A, Jain A, Corcoran D, et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: Evidence from human and murine studies. Pediatr Res 2014; 76: 238–244.
Al-lawama M, Alammori I, Abdelghani T, et al. Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. J Int Med Res 2018; 46: 811–818.
Härkin P, Härmä A, Aikio O, et al. Paracetamol Accelerates Closure of the Ductus Arteriosus after Premature Birth: A Randomized Trial. J Pediatr 2016; 177: 72–77.
Parvin Akbari Asbagh, Mohammad Reza Zarkesh, Firoozeh Nili, Fatemeh Sadat Nayeri ATN. Prophylactic teatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran Univ Med J 2018; 73: 4–6.
B. S, Patel S, N. G. IV Paracetamol for closure of patent ductus arteriosus in preterm neonates admitted to a tertiary care centre. Int J Contemp Pediatr 2018; 5: 294.
Rizky Adriansyah, Nikmah S. Idris, Mulyadi M. Djer, Sukman T. Putra RR. Intravenous paracetamol and patent ductus arteriosus closure in preterm infants. Paediatr Indones 2011; 51: 207– 212.
Tekgündüz KŞ, Ceviz N, Caner I, et al. Intravenous paracetamol with a lower dose is also effective for the treatment of patent ductus arteriosus in pre-term infants. Cardiol Young 2015; 25: 1060–1064.
El Hajjar M, Vaksmann G, Rakza T, et al. Severity of the ductal shunt: A comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005 Sep; 90(5):F419-22.
Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39: 1890–1900.
Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006; 89: 330–335.
Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation 2006; 114: 1873–1882.
Oncel MY, Yurttutan S, Degirmencioglu H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013; 103: 166–169.
Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: A randomized controlled trial. J Pediatr 2014; 164: 1–2.
Yurttutan S, Oncel MY, Arayici S, et al. A different first-choice drug in the medical management of patent ductus arteriosus: Oral paracetamol. J Matern Neonatal Med 2013; 26: 825–827.
Özdemir ÖM, Doǧan M, Küçüktaşçi K, et al. Paracetamol therapy for patent ductus arteriosus in premature i̇nfants: A chance before surgical ligation. Pediatr Cardiol 2014; 35: 276–279.
Jasani B, Kabra N, Nanavati RN. Oral paracetamol in treatment of closure of patent ductus arteriosus in preterm neonates. J Postgrad Med 2013; 59: 312–314.
Kessel I, Waisman D, Lavie-Nevo K, et al. Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: A case series. J Matern Neonatal Med 2014; 27: 1719–1721.
Terrin G, Conte F, Scipione A, et al. Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Ital J Pediatr 2014; 40: 1–2.
Nadir E, Kassem E, Foldi S, et al. Paracetamol treatment of patent ductus arteriosus in preterm infants. J Perinatol 2014; 34: 748–749.
Dang D, Wang D, Zhang C, et al. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: A randomized controlled trial. PLoS One 2013; 8: 1–2.
El-Mashad AER, El-Mahdy H, El Amrousy D, et al. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. Eur J Pediatr 2017; 176: 233–240.
Yang B, Gao X, Ren Y, et al. Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: A randomized controlled trial. Exp Ther Med 2016; 12: 2531–2536.
Copyright (c) 2021 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
